Literature DB >> 1882111

Mycobacterium kansasii infections in Western Australia (1962-1987).

S C Pang1.   

Abstract

The records of 81 patients with isolations of Mycobacterium kansasii in Western Australia over 26 years have been reviewed. Thirty-nine individuals with 40 episodes of infection were considered to have disease due to M. kansasii: 36 in the lungs (90%), two in the joints (5%), and one each in the skin (2.5%) and the lymph nodes (2.5%). The average incidence rate per 100,000 per year was 0.14 for the state with the highest in the Geraldton Mid-west region (0.57). The male:female ratio was 4:1 and the mean age 50 years (SD 14.5). For pulmonary disease the male:female ratio was 3.5:1, the mean age 53 years (SD 11), 42% being miners or ex-miners and 91% smokers or ex-smokers. Almost 97% of those infected were Caucasian and none were Aboriginal. Drug treatment was highly successful, particularly with the rifampicin/ethambutol combination, where 12 months appeared to be adequate. There are differences in the demography of the patients having pulmonary disease compared to the 42 with insignificant isolations.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1882111     DOI: 10.1016/s0954-6111(06)80082-x

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  8 in total

1.  Management of opportunist mycobacterial infections: Joint Tuberculosis Committee Guidelines 1999. Subcommittee of the Joint Tuberculosis Committee of the British Thoracic Society.

Authors: 
Journal:  Thorax       Date:  2000-03       Impact factor: 9.139

2.  Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries.

Authors:  Jennifer Adjemian; Kenneth N Olivier; Amy E Seitz; Steven M Holland; D Rebecca Prevots
Journal:  Am J Respir Crit Care Med       Date:  2012-02-03       Impact factor: 21.405

3.  Nasal Mycobacterium kansasii infection in a patient with acquired immunodeficiency syndrome.

Authors:  E Tortoli; M T Simonetti; D Dionisio
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-07       Impact factor: 3.267

4.  Pulmonary Mycobacterium kansasii infection: comparison of the clinical features, treatment and outcome with pulmonary tuberculosis.

Authors:  S A Evans; A Colville; A J Evans; A J Crisp; I D Johnston
Journal:  Thorax       Date:  1996-12       Impact factor: 9.139

5.  Diagnostic and therapeutic management of atypical mycobacterial infections in children.

Authors:  I Dhooge; C Dhooge; F De Baets; P Van Cauwenberge
Journal:  Eur Arch Otorhinolaryngol       Date:  1993       Impact factor: 2.503

6.  Mycobacterium kansasii pulmonary infection: a prospective study of the results of nine months of treatment with rifampicin and ethambutol. Research Committee, British Thoracic Society.

Authors: 
Journal:  Thorax       Date:  1994-05       Impact factor: 9.139

7.  Changing epidemiology of pulmonary nontuberculous mycobacteria infections.

Authors:  Rachel M Thomson
Journal:  Emerg Infect Dis       Date:  2010-10       Impact factor: 6.883

8.  Clinical Significance of Mycobacterium kansasii Isolates from Respiratory Specimens.

Authors:  Seong Mi Moon; Hye Yun Park; Kyeongman Jeon; Su-Young Kim; Myung Jin Chung; Hee Jae Huh; Chang-Seok Ki; Nam Yong Lee; Sung Jae Shin; Won-Jung Koh
Journal:  PLoS One       Date:  2015-10-02       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.